medicine

The Spanish Minister of Health, Dolors Montserrat, defended on Wednesday that the current political debate in Catalonia, where the government plans to hold an independence referendum in autumn, does not damage Barcelona's candidacy to host the European Medicines Agency. In comments to the press from Brussels, where she held meetings with the Health Commissioner Vytenis Andriukaitis and the Secretary-Generals of the Commission and the Council, Montserrat said that “no one” had raised the issue of independence. “We are the government of all Catalans and we want the EMA in Barcelona. I am strongly convinced that (the independence debate) does not affect this at all. No one has asked me about it,” she insisted. Montserrat said that the Catalan capital is already “ready” to host the 900 EMA staff members at the iconic Torre Agbar building and said that Barcelona “fulfills” all the criteria.

He was the director of the prestigious ophthalmologist clinic Barraquer in Barcelona, founded in 1947 by his father and world-renowned doctor Ignasi Barraquer. Joaquim Barraquer was Professor of Eye Surgery at the Universitat Autònoma de Barcelona and Honorary Professor and Doctor Honoris Causa at several other universities. He was a specialist in corneal transplants and eye surgery to treat cataracts, glaucoma and myopia.

The initiative will set up Catalonia as a point of reference in Europe regarding this kind of medicine. The agreement between the Catalan government and a consortium led by the Beijing government also includes actions in the fields of higher education, research, health and culture. For example, an official master’s degree in Chinese traditional medicine will be taught in collaboration with two Catalan universities, the Universitat de Barcelona (UB) and the Universitat Pompeu Fabra (UPF), and alongside with Beijing University of Chinese Medicine. The project has been promoted by the Catalan Ministry for Business and Knowledge, through the area which focuses on attracting foreign investment, ACCIÓ – Catalonia Trade & Investment, and the Secretary for Universities and Research.

On Wednesday the World Health Organisation (WHO) appointed Barcelona-based researcher Pedro Alonso as the new Director of its Global Malaria Program. Alonso is a key figure in the global fight against malaria and has lead research into a vaccine to combat the life-threatening illness. He has been involved with WHO since 2011, when the organisation appointed him as the Chair of the GTS Steering Committee on the Global Technical Strategy on Malaria. Alonso is currently the Director of the Barcelona Institute for International Health Research. He is also the Head of the Department of International Health and Tropical Medicine at Barcelona's Hospital Clínic and a lecturer at Barcelona University. The physician is due to start his new position in October and is expected to give his formal recommendation on the strategy against malaria in the first quarter of 2015.

Catalonia has established a reputation as a global centre of scientific excellence, pioneering research and innovative ideas. This corner of Europe, with just 0.1% of the world’s population, accounts for nearly 1% of global scientific production. The Catalan Research system, formed of 12 internationally esteemed universities, over 60 research centres, 15 world class hospitals, and almost 9,000 innovative companies, attests to the Catalonia's ambitions in science. This territory is also a magnet of international funding: with 1.5% of Europe’s population, it receives 2.2% of European competitive funds and 3.5% of European Research Council (ERC) grants. There can be no doubt that Catalonia is now a benchmark in Southern Europe, producing frontier research and punching considerably above its weight in terms of scientific contribution.  It is attracting worldwide talent and projects, and many consider it to be fast becoming the Palo Alto of biomedical research.

Barça's first team have started the preseason with a series of examinations of their physical condition. Eleven first team players (Ter Stegen, Masip, Montoya, Bartra, Adriano, Sergi Roberto, Rafinha, Deulofeu, Afellay, Tello and Bojan) were joined by thirteen from the reserves (Patric, Ie, Bagnack, Diagne, Grimaldo, Samper, Halilovic, Munir, Sandro, Dani Nieto, Joan Roman, Dongou and Adama). . After initial analyses, they were then staggered into different groups for biomechanical tests, electrocardiograms, echographies, effort tests and densitometry examinations. On Saturday, Huelva will be the stage for the first preseason friendly for Barça 2014/15.

A team of surgeons at the Sant Joan de Déu Hospital in the Catalan capital successfully removed a tumour from a five year old child by first preparing and practicing the “highly complex” procedure on a 3D printed tumour. The child had neuroblastoma, a difficult cancer to extirpate because of the surrounding blood vessels and arteries. In such cases, testing the procedure in advance "is key" because it allows surgeons to study the most effective way of extracting the tumour without damaging other tissues, and to test the method before surgery. This has been possible thanks to the use of a 3D replica of the tumour.

Scientists at the Universitat Autònoma de Barcelona (UAB) have found that an alteration of a neuronal gene program plays an essential role in the first stages of Alzheimer's disease and have developed a gene therapy which is effective on mice. The Catalan study occupies the front page of 'The Journal of Neuroscience'. Researchers have identified a new mechanism that regulates the expression of genes in the brain which are essential for the function of neuronal circuits involved in learning and memory. According to the new study, which was carried out by Dr. Carlos Saura's group at the UAB's Institute of Neurosciences (Institut de Neurociències), the alteration of a gene program mediating neuronal transmission and survival may underlie memory loss at early pathological stages of Alzheimer's disease (AD).

A total of 23,825 patients have to wait longer than the maximum 6-month-period to undergo one of the 14 surgeries with a guaranteed waiting time, according to the Catalan Minister of Health, Boi Ruiz. In 2013, a total of 151,009 patients underwent one of these surgeries, 3,834 more than the previous year, which represents a 2.6% increase. The number of patients who still require one of these 14 procedures in December 2013 has increased by 6% and 4,261 people, reaching 75,075 with an average waiting time of 5.78 months. On the other hand, the waiting lists for all surgeries, including the 14 specific procedures, have fallen by about 7,000 people in 2013 compared to 2012.

Barcelona’s Hospital Clínic has installed the ‘Micra’ 24mm pacemaker - equivalent to the size of a one euro coin -  in 4 patients as part of a clinical trial involving 10 medical centres and 60 patients troughout the world. This innovative wireless system is minimally invasive since it does not require any surgical procedure but is implanted in the heart through the femoral vein using a catheter. Such a procedure can be performed within 30 minutes and also reduces the patients’ risks of future infections. According to the Medical Director of the Hospital, Josep Brugada, if the clinical study is successful, it will involve a “paradigm shift”. Experts estimate it could reach hospitals within the next two or three years.

A clinical trial conducted in nine Catalan health care centres and published in the ‘British Medical Journal’ found that “in the case of mild respiratory infections such as acute bronchitis, there is a misuse of antibiotics, which is of no benefit to patients, and only helps increasing resistance to these drugs”. The study has been coordinated by the prestigious Vall d’Hebron Research Institute (VHIR). From 2010 to 2012, 416 patients, who showed several signs of acute bronchitis, were randomly assigned one of three different treatments. The main conclusion was that antibiotics, the most widely prescribed treatment for this type of illness, are ineffective. The study also showed that anti-inflammatory treatments increased in a minimal way the chances of ending coughs faster.

Researchers from Barcelona’s Centre for Regenerative Medicine (CMRB), the Catalan capital’s Hospital Clínic and the Salk Institute of California have successfully created three-dimensional renal structures which are virtually indistinguishable from embryonic kidneys. They have started creating kidney cells from human stem cells, and ultimately proven that these newly created cells could aggregate in vitro to form a “micro-kidney”. The team led by Juan Carlos Izpisúa, from the CMRB, said that this scientific breakthrough would facilitate the study of kidney diseases and enable scientists to work on new treatments. He added that this achievement was a great step towards developing therapies based on the use of stem cells.

The Catalan Institute of Oncology (ICO) has introduced a world pioneering technique which allows four out of five patients who cannot undergo surgery to survive the illness. This technique causes less after-effects than the traditional radiotherapy. Furthermore, statistics show that with the regular treatment, two thirds of these patients die. However, Ferran Gadea, the Head of the Radiotherapy and Oncology Service, says that the best option to cure a lung cancer is still to undergo the operation when possible.

A better use of body organs has led to an increase in transplant rates in Catalonia despite a lower number of donors. In 2012, 872 organ transplants were made in Catalan hospitals and waiting lists were reduced by 4.6%. Lung transplants increased by 35% and heart donors increased by 18.7%.

The scientists working at the HIVACAT project for the development of an effective cure against the HIV virus are hopeful of finding a vaccine in the near future that would stop patients having to be treated for their whole life, actually eradicating the disease. The researchers have tested a first vaccine that has proved effective in reducing the viral load by up to 95%. However, the vaccine effects are only temporary, so researchers will continue the investigation in order to achieve a permanent effect.